William Trenton Webb Sells 1,794 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) insider William Trenton Webb sold 1,794 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $13.86, for a total value of $24,864.84. Following the completion of the sale, the insider directly owned 72,455 shares of the company’s stock, valued at $1,004,226.30. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

William Trenton Webb also recently made the following trade(s):

• On Friday, March 6th, William Trenton Webb sold 272 shares of Surgery Partners stock. The shares were sold at an average price of $13.93, for a total value of $3,788.96.

Surgery Partners Stock Down 2.6%

SGRY stock opened at $12.95 on Wednesday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -20.89 and a beta of 1.95. Surgery Partners, Inc. has a fifty-two week low of $12.25 and a fifty-two week high of $24.60. The stock has a fifty day moving average of $15.10 and a 200-day moving average of $17.93.

Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The firm had revenue of $885.00 million during the quarter, compared to analysts’ expectations of $866.54 million. During the same period last year, the business posted $0.44 EPS. The company’s revenue was up 2.4% compared to the same quarter last year. As a group, equities research analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.

Surgery Partners announced that its Board of Directors has approved a share buyback plan on Thursday, February 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 9.7% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Pentwater Capital Management LP grew its position in shares of Surgery Partners by 66.9% during the 3rd quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after purchasing an additional 4,681,000 shares in the last quarter. UBS Group AG raised its position in shares of Surgery Partners by 111.4% in the fourth quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after buying an additional 4,113,052 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Surgery Partners by 528.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock valued at $30,277,000 after buying an additional 1,647,714 shares during the period. Glenview Capital Management LLC bought a new stake in Surgery Partners during the second quarter valued at $33,995,000. Finally, King Street Capital Management L.P. grew its position in Surgery Partners by 24.5% during the second quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock worth $138,382,000 after buying an additional 1,225,000 shares in the last quarter.

Surgery Partners News Summary

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus remains constructive — several brokerages rate SGRY as a “Moderate Buy,” which supports baseline investor demand. Brokerage Recommendation
• Positive Sentiment: Investor conference access: Management presented at the Barclays 28th Annual Global Healthcare Conference (Mar 10), providing a forum to reiterate guidance and margin improvement plans — useful upside catalyst if commentary is clear and credible. Prepared Remarks Transcript
• Positive Sentiment: Short interest fell ~15.7% in February (still ~11% of float but lower than mid‑month), which reduces one source of bearish positioning and could limit further short-driven price pressure.
• Neutral Sentiment: Prepared remarks and Q4 write‑ups: Recent transcripts and industry Q4 summaries provide more detail on volumes and outpatient trends but contain no single new, market‑moving disclosure. Q4 Coverage
• Negative Sentiment: Activist pressure: Ortelius Capital is pushing for board changes and asset sales, increasing the chance of near‑term strategic disruption, management turnover or contentious proxy fights. Activist Story
• Negative Sentiment: Fraud probe announced: Law firm Levi & Korsinsky opened an investigation into prior management statements on margin expansion, raising potential legal/settlement risk and heightening investor uncertainty. Fraud Investigation
• Negative Sentiment: Significant insider selling: Multiple executives (CEO, CFO and other officers) sold sizable blocks the week of Mar 5–6 at roughly $13.60–$13.93, which the market often interprets negatively for near‑term confidence. Representative SEC filing: CEO Sale Filing
• Negative Sentiment: Recent earnings execution: The March 2 Q4 report showed a meaningful EPS miss (revenue slight beat but EPS well below street), highlighting execution/margin risk that underpins some of the legal and activist scrutiny.

Analysts Set New Price Targets

SGRY has been the topic of a number of analyst reports. TD Cowen lowered their target price on shares of Surgery Partners from $28.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Royal Bank Of Canada reduced their price target on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, March 4th. UBS Group decreased their price objective on Surgery Partners from $29.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Jefferies Financial Group reissued a “buy” rating on shares of Surgery Partners in a report on Wednesday, March 4th. Finally, Mizuho reduced their target price on Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.60.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.